Introduction
Abdominal pain is a common but often overlooked symptom in patients with ulcerative colitis (UC). The causes of pain during deep remission remain incompletely known, although factors in the brain-gut axis may play a role.
Aims & Methods
The aim of this study was to determine factors associated with abdominal pain in UC patients. Three existing study cohorts of adults with UC were used. Cohort I included 133 patients (49 active), cohort II 287 patients (155 active) and cohort III 92 patients (20 active). The abdominal pain domain of the Gastrointestinal Symptom Rating Scale was used to assess the severity of pain, identifying subjects with at least mild severity of abdominal pain. The Hospital Anxiety and Depression Scale was used to identify subjects with anxiety and or depression (scores ≥8) Patients also completed questionnaires to assess severity of fatigue (Fatigue Impact Scale (FIS, cohort I)), and quality of life (QoL, the IBD questionnaire (IBDQ, cohort II)).
Results
In the three cohorts 39%, 24% and 20% of the patients with active disease and 20%, 7% and 15% of the patients in remission reported at least mild severity of abdominal pain. A higher proportion of UC patients with at least mild abdominal pain had anxiety (83%, 44%, and 40% vs 42%, 18% and 7%; p<0.01) and depression (40%, 33% and 40% vs 13%, 9% and 13% p<0.05). Disease-specific QoL was lower in patients with at least mild abdominal pain, both in patients with active disease (median [IQR] IBDQ score 182 [150-198] vs 144 [115-160], p<0.001) and in remission (IBDQ score 203 [190-213] vs 171 [141-181], p<0.001). In UC patients in remission, having at least mild abdominal pain was associated with more severe impact of fatigue on daily life, (FIS 81 [67-100] versus 29 [14-58], p<0.001).
Conclusion
Abdominal pain is relatively common in patients with UC with active disease as well as in remission. This is associated with anxiety, depression and more severe fatigue and a lower QoL. Hence, paying attention to abdominal pain and associated factors seems important to optimize clinical management of these patients.
Disclosure
Tom van Gils: None
Hans Törnblom: Consultant/Advisory Board member: Cinclus Pharma, Dr Falk Pharma Gmbh, VIPUN Medical.
Speakers’ bureau: Tillotts, Takeda, Galapagos
Börje Jonefjäll: Consultant/advisory board member: Tillots. Speaker for MSD, AbbVie, Tillotts, MEDA, and Takeda.
Hans Strid: Consultant/Advisory Board member: Tillotts, Takeda, Abbvie, Pharmacosmos, BMS
Magnus Simrén: Unrestricted research grants: Glycom/DSM, Genetic Analysis AS
Consultant/Advisory Board member: Danone Nutricia Research, Ironwood, Biocodex, Genetic Analysis AS, Tillotts, Takeda, Arena, Kyowa Kirin, Abbvie, BioGaia, Cinclus Pharma and Pharmanovia.
Speakers’ bureau: Tillotts, Kyowa Kirin, Takeda, Biocodex, Sanofi, Janssen Immunology, Pfizer, Ferrer, BioGaia and Falk Foundation.